{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059107","form_type":"8-K","ticker":null,"cik":"0001697532","company_name":"Applied Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.642373+00:00","generated_at":"2026-06-02T06:26:24.824869+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Applied Therapeutics Q1 net loss $83.9M; govorestat NDA PDUFA Nov 28, 2024","bullets":["Net loss $83.9M ($0.67/share) vs $10.1M ($0.18/share) Q1 2023; cash $146.5M up from $49.9M.","Govorestat NDA for Classic Galactosemia under priority review; PDUFA date Nov 28, 2024.","MAA under EMA review; decision expected early Q1 2025 after Day 120 clock-stop extension.","Discussing potential NDA submission for SORD Deficiency under Accelerated Approval with FDA.","Appointed Dale Hooks as Chief Commercial Officer; presented Phase 3 ARISE-HF data at ACC."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059107","json":"https://secwatch.observer/filing/0001104659-24-059107.json","markdown":"https://secwatch.observer/filing/0001104659-24-059107.md","text":"https://secwatch.observer/filing/0001104659-24-059107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1697532/000110465924059107/0001104659-24-059107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1697532/000110465924059107/tm2413888d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:26:24.824869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7de25a90c863e028a53dcbcdc69fc748073606d","claim":"Applied Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $146.5 million, net income $83.9 million, EPS $0.67 per basic and diluted common share.","evidence_excerpt":"full study results were published in the Journal of the American College of Cardiology (JACC). Financial Results · Cash and cash equivalents and short-term investments totaled $146.5 million as of March 31, 2024, compared with $49.9 million at December 31, 2023. · Research and development expenses for the three months ended March 31, 2024, were $12.2 million,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1697532/000110465924059107/0001104659-24-059107-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$146.5 million"},{"label":"Net income","value":"$83.9 million"},{"label":"EPS","value":"$0.67 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}